Related references
Note: Only part of the references are listed.Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin
Davide Gatti et al.
BONE (2012)
Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women
Y. E. Chung et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1α levels in patients with MGUS
Alvin C. Ng et al.
BLOOD (2011)
Effects of estrogen on osteoprogenitor cells and cytokines/bone-regulatory factors in postmenopausal women
Ulrike I. Moedder et al.
BONE (2011)
Regulation of Circulating Sclerostin Levels by Sex Steroids in Women and in Men
Ulrike Il Moedder et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Acute Decline in Serum Sclerostin in Response to PTH Infusion in Healthy Men
Elaine W. Yu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
The Waning of Teriparatide Effect on Bone Formation Markers in Postmenopausal Osteoporosis Is Associated with Increasing Serum Levels of DKK1
Davide Gatti et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Evidence That Dkk-1 Is Dysfunctional in Ankylosing Spondylitis
Dimitrios Daoussis et al.
ARTHRITIS AND RHEUMATISM (2010)
The Wnt signaling pathway and rheumatoid arthritis
Francieli de Sousa Rabelo et al.
AUTOIMMUNITY REVIEWS (2010)
Perspectives assessment of involutional bone loss: Methodological and conceptual problems
Silvano Adami et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Effects of Parathyroid Hormone Treatment on Circulating Sclerostin Levels in Postmenopausal Women
Matthew T. Drake et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Serum Sclerostin Levels Negatively Correlate with Parathyroid Hormone Levels and Free Estrogen Index in Postmenopausal Women
Faryal S. Mirza et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Treatment of osteoporosis with denosumab
E. Michael Lewiecki
MATURITAS (2010)
Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock-In Mice That Express Chimeric (Murine/Human) RANKL
Paul J. Kostenuik et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Giant Osteoclast Formation and Long-Term Oral Bisphosphonate Therapy
Robert S. Weinstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Steven R. Cummings et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma
Martin Kaiser et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2008)
Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin
Alexander G. Robling et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Minireview:: Targeting the Wnt/β-catenin pathway to regulate bone formation in the adult skeleton
Roland Baron et al.
ENDOCRINOLOGY (2007)
Bone density ligand, sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity
Debra L. Ellies et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia
Ji Li et al.
BONE (2006)
Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesis
T Bellido et al.
ENDOCRINOLOGY (2005)
SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor
M Semënov et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Osteoclast-derived activity in the coupling of bone formation to resorption
TJ Martin et al.
TRENDS IN MOLECULAR MEDICINE (2005)
The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma
E Tian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women
G Eghbali-Fatourechi et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism
J Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)